

UCLA

UCLA Previously Published Works

Title

The serine/threonine-protein kinase/endoribonuclease IRE1 α protects the heart against pressure overload-induced heart failure

Permalink

<https://escholarship.org/uc/item/56j6v9n6>

Journal

Journal of Biological Chemistry, 293(25)

ISSN

0021-9258

Authors

Steiger, DeAnna
Yokota, Tomohiro
Li, Jin
et al.

Publication Date

2018-06-01

DOI

10.1074/jbc.ra118.003448

Peer reviewed



The serine/threonine-protein kinase/endoribonuclease IRE1 α protects the heart against pressure overload–induced heart failure

Received for publication, April 14, 2018, and in revised form, May 4, 2018. Published, Papers in Press, May 16, 2018, DOI 10.1074/jbc.RA118.003448

DeAnna Steiger^{†1,2}, Tomohiro Yokota^{†1,3}, Jin Li[‡], Shuxun Ren[‡], Susumu Minamisawa[§], and Yibin Wang^{†4}

From the [†]Departments of Anesthesiology, Physiology, and Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California 90095 and the [§]Department of Cell Physiology, Jikei University School of Medicine, Tokyo 105-8461, Japan

Edited by Wolfgang Peti

Heart failure is associated with induction of endoplasmic reticulum (ER) stress and the unfolded protein response (UPR). The serine/threonine protein kinase/endoribonuclease IRE1 α is a key protein in ER stress signal transduction. IRE1 α activity can induce both protective UPR and apoptotic downstream signaling events, but the specific role for IRE1 α activity in the heart is unknown. A major aim of this study was to characterize the specific contribution of IRE1 α in cardiac physiology and pathogenesis. We used both cultured myocytes and a transgenic mouse line with inducible and cardiomyocyte-specific IRE1 α overexpression as experimental models to achieve targeted IRE1 α activation. IRE1 α expression induced a potent but transient ER stress response in cardiomyocytes and did not cause significant effects in the intact heart under normal physiological conditions. Furthermore, the IRE1 α -activated transgenic heart responding to pressure overload exhibited preserved function and reduced fibrotic area, associated with increased adaptive UPR signaling and with blunted inflammatory and pathological gene expression. Therefore, we conclude that IRE1 α induces transient ER stress signaling and confers a protective effect against pressure overload–induced pathological remodeling in the heart. To our knowledge, this report provides first direct evidence of a specific and protective role for IRE1 α in the heart and reveals an interaction between ER stress signaling and inflammatory regulation in the pathologically stressed heart.

Cardiovascular diseases are the number one cause of mortality in the United States and worldwide (1). Treatments for heart failure remain elusive due to the complexity of etiology and our

limited understanding of the underlying mechanisms. Protein homeostasis is critical to cellular health, and defects in protein synthesis, maturation, and turnover are implicated in many human diseases (2–5), including heart failure (6). Protein homeostasis in the ER⁵ lumen is monitored and maintained by highly conserved quality control mechanisms (7). Disruptions to ER homeostasis, including altered redox status, calcium flux, protein aggregation, or accumulation of client proteins, cause ER stress and activation of a highly conserved unfolded protein response (UPR) (also known as ER stress response) (8–10). The UPR conveys stress from the ER to the nucleus (11, 12), culminating in activation of transcription factors to up-regulate chaperone molecules and to suppress protein synthesis, leading to restored ER homeostasis (13). There are three major ER stress sensors and signal transducers involved in UPR, including activating transcription factor 6 (ATF6), protein kinase-like ER kinase (PERK), and inositol-requiring 1 (IRE1). They act in concert to restore protein folding in the ER lumen by reducing the client protein folding load, while increasing protein folding capacities and enhancing protein degradation for misfolded peptides, through coordinated induction of chaperone genes and inhibition of protein synthesis (14–18).

In the heart, ER stress signaling is activated in response to a broad spectrum of myocardial injuries, including ischemia, ischemia/reperfusion, hypoxia, and mechanical overload (6, 8, 19–24). ER stress signaling is also implicated in metabolic remodeling in the diseased heart (25). However, it remains unclear whether ER stress signaling is protective or detrimental to the heart. Some studies suggest that ER stress contributes to myocyte apoptosis and heart failure (21, 22, 26, 27), whereas other reports indicate that it is cardioprotective (24, 28, 29). Different ER stress pathways appear to have specific roles in the heart. ATF6-mediated signaling has been identified as a highly protective pathway against ischemia/reperfusion injury (24) by inducing BiP and GRP94. Similarly, Xbp1, downstream of

This work was supported in part by National Institutes of Health Grants HL103205 and HL070079 (to Y. W.) and additional funding from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (to S. M.), the Vehicle Racing Commemorative Foundation (to S. M.), The Jikei University Graduate Research Fund (to S. M.), and the MEXT Supported Program for the Strategic Research Foundation at Private Universities (to S. M.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

¹ Both authors contributed equally to this work.

² Supported by National Institutes of Health Ruth L. Kirschstein National Research Service Award F31 AG038156.

³ Supported by a UCLA-Waseda Brain Circulation fellowship award from the Japanese Ministry of Science and Technology.

⁴ To whom correspondence should be addressed. E-mail: yibinwang@mednet.ucla.edu.

⁵ The abbreviations used are: ER, endoplasmic reticulum; UPR, unfolded protein response; ATF6, activating transcription factor 6; PERK, protein kinase-like ER kinase; IRE1, inositol-requiring 1; ANF, atrial natriuretic factor; BNP, brain natriuretic factor; TNF, tumor necrosis factor; IL, interleukin; TM, tunicamycin; JNK, c-Jun N-terminal kinase; TAC, transverse aortic constriction; MAPK, mitogen-activated protein kinase; H&E, hematoxylin and eosin; NRVM, neonatal rat ventricular myocyte; BisTris, 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol; p-, phosphorylated; LVID, diastolic/systolic diameter in the left ventricle; LVPW, diastolic/systolic posterior wall thickness in the left ventricle; adv, adenovirus.




Figure 1. The functional impact of IRE1 α activity in cells. *A*, representative images of adv-GFP- and adv-IRE1 α -treated INS-1 cells. *B*, RT-PCR detection of spliced Xbp1 (*sXbp1*) levels in adv-IRE1 α -treated INS-1 cells and quantification of the signal intensity as labeled. TM-treated cells are used as a positive control. *C*, immunoblots for the expression and autophosphorylation of IRE1 α as well as ER stress-related proteins in adv-IRE1 α -treated INS-1 cells and quantification of the signal intensity normalized by actin as labeled. *D*, immunoblots for stress-activated proteins p38 MAPK and JNK in adv-IRE1 α -treated INS-1 cells and quantification of the signal intensity normalized by actin as labeled. ND, not detected.

IRE1 α activation, was found to be protective against hypoxia and myocardial infarction also by inducing BiP (30) and coupling with hexosamine biosynthetic pathway (25). BiP expression can inhibit apoptotic signal CHOP and reduces apoptosis in cardiomyocytes (31). However, ER stress can also activate cell death signaling pathways (32–34). In particular, IRE1 α binds to TRAF2 and activates downstream ASK1, resulting in JNK and p38 MAPK activation and apoptotic cell death (14, 35, 36). In contrast, other reports indicate that interactions between IRE1 α and TRAF2 and JNK activate autophagy to promote cell survival during ER stress (37). PERK can also contribute to apoptotic signaling by promoting expression of ATF4 (17, 38, 39), a transcriptional activator for CHOP (40, 41). Angiotensin II, along with tunicamycin and thapsigargin, can induce both adaptive protein folding chaperones and apoptotic signal CHOP (6). ER stress can also induce hypertrophy gene expression, including atrial natriuretic factor (*ANF*) and brain natriuretic factor (*BNF*), suggesting that ER stress contributes to both adaptive and pathological remodeling. Finally, ER stress is implicated in cancer therapy Imatinib-induced cardiomyopathy (26). Although evidence is clear about the importance of ER stress regulation in cardiac pathogenesis, the specific contribution of IRE1-mediated signaling in the heart has not yet been directly investigated.

In the current study, we investigated the direct impact of IRE1 α activation in the heart. In cardiomyocytes in culture, IRE1 α overexpression induced significant IRE1 α autophosphorylation and Xbp1 activation, as expected. However, there was no evidence of induction in cell death, stress signaling, or hypertrophy upon prolonged IRE1 α expression. Using an animal model with heart-specific, tamoxifen-inducible IRE1 α overexpression, we investigated the direct impact of IRE1 α expression *in vivo*. Overexpression of IRE1 α did not lead to any

pathological phenotype at baseline. Following pressure overload induced by trans-aortic constriction, IRE1 α expression in transgenic hearts showed better preserved function, blunted pathologic marker gene induction, and better preserved ER stress signaling. More interestingly, the expression of inflammatory cytokines TNF α and IL-6 was significantly blunted by IRE1 α expression, suggesting that IRE1 α -mediated ER stress signaling inhibits inflammatory cytokine induction in the heart. Thus, IRE1 α activity has a direct protective effect in the heart against pressure overload-induced cardiac pathology, involving suppression of pro-inflammatory gene expression.

Results

IRE1 α induces adaptive and transient UPR in cardiac myocytes

To investigate the functional impact of IRE1 α activity, we generated adenoviral vectors expressing WT IRE1 α . To validate the functionality of this expression vector, we tested the adenoviral vector in INS-1 cells. As shown in Fig. 1, IRE1 α expression in INS-1 cells led to significant cell death 2 days after transfection (Fig. 1A). Xbp1 splicing was induced in a dose-dependent manner by IRE1 α expression, similar to tunicamycin (TM) treatment (Fig. 1B). In addition, IRE1 α autophosphorylation, BiP expression, phospho-EIF2 α (Fig. 1C), and JNK kinase activity (Fig. 1D) were also induced in a dose-dependent fashion by IRE1 α expression in INS-1 cells. These data are consistent with previous literature where IRE1 α expression promotes cell death, associated with elevated RNase and stress kinase signaling via oligomerization in INS-1 cells (42, 43). In contrast, neonatal rat ventricular myocytes (NRVMs) with IRE1 α overexpression did not show significant difference in morphology or cell sizes (Fig. 2A), although autophosphorylation and downstream Xbp1 activation were detected as in INS-1 cells (Fig. 2, B

IRE1 α function in heart




Figure 2. The functional impact of IRE1 α activity on the cardiomyocyte. *A*, representative images of mock- and adv-IRE1 α -treated NRVMs and cell-surface area. *B*, immunoblots of phospho-IRE1 α , total IRE1 α , Myc, and actin in NRVMs treated with mock, adv-IRE1 α , and adv-IRE1 α KA vectors 2 days post-transfection. *C*, RT-PCR detection of *sXbp1* versus *uXbp1* levels in adv-IRE1 α -treated NRVMs at 2 days post-transfection. *D*, quantitative measurements of mRNA for IRE1 α , BiP, and CHOP in NRVMs treated with adv-IRE1 α for 2 days. *n* = 3, **p* < 0.05. *E*, quantitative measurements of mRNA for IRE1 α , BiP, and CHOP in NRVMs treated with adv-IRE1 α KA for 2 days. *n* = 3, **p* < 0.05. *F*, immunoblots for phospho-IRE1 α in NRVMs treated with adv-IRE1 α or adv-IRE1 α KA for 5 days. *G*, RT-PCR detection of *sXbp1* levels in adv-IRE1 α - or adv-IRE1 α KA-treated NRVMs for 5 days. *H*, mRNA expression of IRE1 α , BiP, and CHOP in NRVMs treated with adv-IRE1 α for 5 days. *n* = 3. A.U., arbitrary units; error bars, S.D.

and *C*). Other ER stress effectors, such as BiP expression, were also significantly induced by IRE1 α overexpression, whereas the pro-apoptotic ER stress gene CHOP was not (*p* = 0.09) (Fig. 2*D*). As expected, expression of a kinase-dead IRE1 α -KA mutant did not affect any of the ER stress molecules (Fig. 2*E*). These results revealed an unexpected myocyte-specific response to IRE1 α expression, where only a subset of cytoprotective ER stress response was triggered in primary cardiomyocytes without activating the pro-apoptotic downstream pathway. Remarkably, prolonged IRE1 α expression (5 days) failed to sustain downstream Xbp1 activation or other UPR gene expression, although IRE1 α autophosphorylation remained elevated (Fig. 2, *F*–*H*). These observations have revealed two specific features in IRE1 α function in cardiomyocytes; one is a selective induction of IRE1 α -mediated cytoprotective response versus stress signaling, and another involves the transient nature of the IRE1 α -induced downstream Xbp1 activation, most likely due to a yet to be identified negative feedback inhibition.

Heart-specific and inducible expression of IRE1 α in mice

To elucidate IRE1 α function in intact heart, we generated an animal model where IRE1 α expression was both inducible and heart-specific using a Cre-loxP-mediated gene switch strategy (Fig. 3*A*) (44). Cre-dependent expression of IRE1 α was demonstrated in 293 cells, validating the efficacy of the construct (Fig. 3*B*). As shown *in vitro*, the Flox-GFP-IRE1 α transgenic mice showed widespread expression of GFP but not the IRE1 α transgene. After cross-breeding with α MHC-Mer-Cre-Mer mice (45–47), the transgenic gene IRE1 α was induced only in ventricular tissue only after tamoxifen treatment (Fig. 3, *C*–*E*). Four weeks after transgene induction, no abnormal phenotype was observed in the IRE1 α -expressing hearts compared with the littermate controls, including non-transgenic or single-transgenic mice, based on morphometric, histological, and functional analysis (Fig. 4). Furthermore, mRNA levels of *sXbp1*, BiP, and CHOP (Fig. 5*A*) were not affected by IRE1 α expression, consistent with our *in vitro* observation after long-term IRE1 α expression. The molecular profiles of ANF,




Figure 3. Establishment of IRE1 α transgenic mouse line. *A*, schematic diagram for cardiac-specific inducible IRE1 α transgenic construct and expected Cre/Lopx-mediated deletion. *B*, immunoblots of phospho-IRE1 α , total IRE1 α , GFP, and actin in HEK293 cells transfected with flox-GFP-IRE1 α vector. *C*, representative RT-PCR detection of IRE1 α expression in different transgenic ventricular tissues from control (Cre $^{-}$ /GFP-IRE1 α $^{-}$) and IRE1 α transgenic (Cre $^{+}$ /GFP-IRE1 α $^{+}$) hearts, with or without tamoxifen (TMX) treatment. *D*, quantification of IRE1 α mRNA expression in heart tissue from the same cohorts as in *C*. *E*, immunoblots of total IRE1 α and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in ventricle, lung, liver, kidney, and skeletal muscle from control (C) and IRE1 α transgenic (I) mice. A.U., arbitrary units; error bars, S.D.

β -MHC, and TNF α were all unchanged following IRE1 α overexpression (Fig. 5B). Together, these observations suggest that IRE1 α expression was not sufficient to sustain ER stress response and did not exert any detrimental effect in the adult mouse heart.

IRE1 α preserves heart function after transverse aortic constriction (TAC)

To test the effect of IRE1 α expression on pathological stress response in heart, IRE1 α transgenic mice were subjected to pressure overload implemented by TAC (48, 49). Pressure overload led to significant loss of cardiac function over time in the control mice. In contrast, the IRE1 α transgenic mice demonstrated preserved function even at 4 weeks post-TAC (Fig. 6A), associated with reduced chamber dilation at the systole (Fig. 6B) based on echocardiograph measurements. Furthermore, the induction of pathological marker genes, including ANF and β MHC, was significantly blunted in response to TAC in the IRE1 α transgenic heart versus the controls (Fig. 6C). However, cardiac hypertrophy as measured from tissue weight and histology was induced by TAC to the same levels in the control versus the IRE1 α transgenic hearts (Fig. 6, D and E). Interestingly, fibrotic induction in myocardium was also significantly blunted in response to TAC in the IRE1 α transgenic heart versus the controls (Fig. 6, E and F).

To investigate the potential mechanism, we analyzed the expression of UPR genes and stress-signaling molecules in

post-TAC hearts. Although there was a trend for lower *BiP* expression in the post-TAC hearts, the IRE1 α heart showed a modestly but significantly higher level of *BiP* expression than controls after TAC (Fig. 7A). In contrast, the mRNA level of *CHOP* was not affected by IRE1 α expression, whereas there was trend for lower expression of *ATF4* in the post-TAC IRE1 α transgenic heart (38) (Fig. 7A). Therefore, IRE1 α expression in the heart leads to better preserved heart function following the TAC with only modest impact on ER stress downstream molecules. ER stress signaling by IRE1 α and TRAF2 has been reported to activate inflammatory signals (50). As shown in Fig. 7B, IRE1 α transgenic hearts showed significantly reduced TAC-induced mRNA expression for both TNF α and *IL-6* cytokines after comparing with the controls. Furthermore, whereas NF- κ B induction was not affected by IRE1 α expression in the post-TAC hearts, the I κ B kinase β induction was significantly blunted in the IRE1 α transgenic hearts, suggesting that attenuated NF- κ B signaling may in part contribute to reduced TNF α /*IL-6* induction in the IRE1 α TAC heart. In summary, IRE1 α expression in the heart protects cardiac dysfunction associated with blunted induction of pro-inflammatory genes.

Discussion

This study provided first comprehensive characterization of the specific function of IRE1 α as one of the three major ER stress-signaling branches in pressure overload-induced cardiac remodeling and dysfunction. In cultured cardiomyocytes,

IRE1 α function in heart




Figure 4. Characterization of IRE1 α transgenic mouse heart at basal conditions. *A*, echocardiogram analysis of ejection fraction (*EF*) and fractional shortening (*FS*) in the IRE1 α transgenic and control mice. *B*, echocardiogram analysis of diastolic/systolic diameter in the left ventricle (*LVID*) and diastolic/systolic posterior wall thickness in the ventricle (*LVPW*). *C*, representative image of H&E-stained hearts from IRE1 α transgenic and control mice. *D*, heart weight/body weight ratio in IRE1 α transgenic and control mice. *E*, body weights 4 weeks after vehicle or tamoxifen injection in both male and female mice. Error bars, S.D.

we observed transient induction of canonical Xbp1 activation following IRE1 α expression without significant effects on cell death and hypertrophy. In intact heart, IRE1 α expression did not affect pressure overload–induced cardiac hypertrophy but significantly attenuated cardiac dysfunction and pathological marker gene expression. Interestingly, IRE1 α expression markedly blunted the induction of pro-inflammatory cytokine gene expression following TAC. Therefore, our results provide direct *in vitro* and *in vivo* evidence that IRE1 α -mediated signaling is cardioprotective, at least in the setting of pressure overload–induced cardiac dysfunction.

ER stress-signaling pathways and the ensuing unfolded protein response are important cellular responses to various insults and have been found to be activated in human congestive heart failure (6), ischemic heart disease (21), and heart failure in response to the cancer drug imatinib (26). Experimental models

have also recapitulated these observations (6, 24), but it is unclear whether ER stress signaling plays protective (24, 30, 31) or pathological roles in heart (22, 26, 51, 52). Expression of a constitutively active ATF6 shows a strong protection against ischemia reperfusion injury in mice (24). CHOP inhibition in NRVMs was also protective against apoptosis in the setting of ER stress by proteasome inhibition (31), and CHOP inactivation *in vivo* protected mouse hearts against apoptosis following ischemia/reperfusion injury (52). Among the three major UPR pathways (*i.e.* IRE1, PERK, and ATF6), IRE1 is unique in terms of diverse downstream outcome. IRE1 activation is capable of both protective and apoptotic signaling through Xbp1 or TRAF2 and stress-activated MAPK signaling cascades, respectively, as demonstrated previously (14, 18, 42, 43, 53, 54) (Fig. 1). However, the molecular nature of IRE1 α function and regulation appears to be highly cell type–specific. Whereas constitu-




Figure 5. ER stress, hypertrophic, and inflammatory gene expression in IRE1 α transgenic mouse heart at basal conditions. *A*, mRNA levels of ER stress-related gene *BiP*, *sXbp1*, and *CHOP* expression in IRE1 α transgenic versus control mouse heart at basal conditions. *B*, hypertrophic markers *ANF* and β *MHC* and inflammatory gene *TNF α* expression in IRE1 α transgenic versus control mouse heart at basal conditions. $n = 3$. A.U., arbitrary units; error bars, S.D.

expression of IRE1 α led to cell death in nonmyocytes, such as INS-1 cells (42), as well as other cell types (54), similar expression in cardiomyocytes achieved only transient induction of *Xbp1* but without cell death induction. More remarkably, prolonged expression led to sustained autophosphorylation of IRE1 α in cardiomyocytes, but only transient induction of *Xbp1*, suggesting the presence of a negative inhibitory feedback mechanism for IRE1 signaling in cardiomyocytes. It is well established that the RNase activity of IRE1 is induced by oligomerization and trans-molecular autophosphorylation (55). However, its inhibition is poorly characterized but may involve Bax inhibitor 1 (56), Hsp90–Cdc37 complex (57), or an ER-specific protein phosphatase (PP2Ce) (58). In cardiomyocytes, *Xbp1*-splicing activity is attenuated over time, whereas the IRE1 α phosphorylation level remains elevated, suggesting that the underlying molecular mechanism may involve uncoupling of its autophosphorylation status and the *Xbp1*-splicing activity. The molecular basis of such negative feedback regulation should be further studied.

We observed that IRE1 α transgenic mice had preserved heart function in response to pressure overload. The underlying mechanism is yet to be uncovered. It is known that inflammatory cytokines are induced in stressed myocardium, contrib-




Figure 6. Preservation of cardiac function in IRE1 α transgenic heart in response to pressure overload. *A*, echocardiogram analysis of EF and FS in the IRE1 α transgenic versus control mouse after TAC. *, $p < 0.05$. *B*, echocardiogram analysis of diastolic/systolic LVID and diastolic/systolic LVPW 4 weeks post-TAC. *, $p < 0.05$. *C*, hypertrophic marker *ANF* and β *MHC* expression after 4 weeks post-TAC. *, $p < 0.05$. $n = 3-4$. *D*, heart weight/body weight in IRE1 α transgenic and control mice 4 weeks post-TAC. ***, $p < 0.001$. *E*, representative image of H&E staining and trichrome staining in IRE1 α transgenic and control mice 4 weeks post-TAC. *F*, quantification results of fibrotic area in IRE1 α transgenic and control mice 4 weeks post-TAC. *, $p < 0.05$. $n = 4-6$. A.U., arbitrary units; error bars, S.D.

IRE1 α function in heart




Figure 7. ER stress and inflammatory gene expression in IRE1 α transgenic mouse heart in response to pressure overload. A, ER stress marker *BiP*, *CHOP*, and *ATF4* mRNA expression. *, $p < 0.05$. $n = 3-4$. B, mRNA levels of inflammatory genes *TNF α* and *IL-6* and NF- κ B signaling genes *NF κ B* and *I κ B kinase β* in control and IRE1 α transgenic hearts following sham or pressure overload. ****, $p < 0.0001$; ***, $p < 0.001$; **, $p < 0.01$; *, $p < 0.05$. $n = 3-4$. A.U., arbitrary units; error bars, S.D.

uting to cardiac dysfunction and pathological remodeling. Indeed, both *TNF α* and *IL-6* expressions were markedly reduced in the post-TAC IRE1 α transgenic hearts. It is reported that both *TNF α* and *IL-6* are induced by stress signaling, such as p38 MAPK (59, 60) and NF- κ B pathway. Although we did not observe any effects on p38 activation, *IKK β* induction was significantly attenuated by IRE1 α expression. The data are consistent with the notion that IRE1 α expression in cardiomyocytes promotes cytoprotective ER stress signaling but not downstream stress signaling and offer a potential mechanistic link between ER stress signaling and anti-inflammatory gene induction in pathologically stressed myocardium. Establishing the cardioprotective role of IRE1 α in the intact heart illustrates the potential contribution of ER stress signaling to the pathogenesis of heart failure as well as the feasibility of targeted manipulation of ER stress signaling for treating the disease.

Experimental procedures

Animal models and surgical procedures

The investigation conformed with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (Publication number 85-23, revised 1985). All procedures were performed in accordance with UCLA animal welfare guidelines and approved by the UCLA institutional animal care and use committee. IRE1 α was cloned into a vector for generation of transgenic animals with Cre-regulated expression of the transgene of interest (61, 62). Transgenic animals were generated in C57/Bl6 background through collaboration

with the UCLA Molecular Genetics Technology Center. Founder animals were identified by PCR with transgene-specific primers.

Animals with heart-specific, inducible IRE1 α overexpression were generated by crossing transgenic founder animals with previously established α MHC-Mer-Cre-Mer (MCM) transgenic mice (47) (45). IRE1 α transgene overexpression was induced by intraperitoneal injection of tamoxifen citrate salt (Sigma), 20 mg/kg body weight/day for 5 days (45). WT and floxed single-transgenic littermate animals treated with tamoxifen or double-transgenic flox-GFP/CRE animals treated with vehicle were also used as controls. Both male and female mice age 12–16 weeks were included in this study.

TAC was performed as described previously with modifications (49). Mice were anesthetized with ketamine (80 mg/kg)/xylazine (20 mg/kg) by intraperitoneal injection. Respiration was provided by mechanical ventilation with 95% O₂ (tidal volume 0.5 ml, 130 breaths/min). Left parasternal thoracotomy was performed to access the transverse aorta, which was tied with a 5-0 nylon suture on a 27-gauge needle. The needle was removed, leaving in place a 65–70% constriction of the aortic lumen. Constriction of the aorta was confirmed by measuring differential blood flow through the right and left carotid arteries 1 week after surgery.

Animals were continuously anesthetized with 1.5% isoflurane and 95% oxygen. VisualSonics Vevo 770 and Vevo 2100 imaging systems and a 30-mHz scan head (Toronto, Canada) were used to collect short and long axis B-mode and M-mode

views. Reported values refer to short-axis measurements and calculations.

Histology

Hearts were perfused and fixed in 10% formalin before embedding in paraffin. All short-axis sections were prepared from mid-ventricle. Sections of 4- μ m heart were deparaffinized and rehydrated before staining by hematoxylin and eosin (H&E) or Masson trichrome and Verhoeff–Van Gieson stain. Stained tissue sections were recorded as digital images by the Aperio XT whole-slide scanning system, and snapshot images were taken using the ImageScope software (Aperio Technologies, Vista, CA).

Cell culture

293 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. Lipofectamine reagent (Life Technologies, Inc.) was used according to the manufacturer's protocol to achieve overexpression of the flox-GFP-IRE1 α construct. INS-1 cells were cultured in RPMI1640 according to published methods (57). NRVMs were harvested from 1–3-day-old Sprague–Dawley rat pups as described previously (63) and cultured in serum-free Dulbecco's modified Eagle's medium supple-

mented with 1% penicillin/streptomycin and 1 \times Insulin-Transferrin-Selenium (ITS). NRVMs were infected with adenovirus (multiplicity of infection of 10) and incubated for 2 days before additional treatment with 5 g/ml TM for 4 h. Experiments with prolonged IRE1 α expression were incubated for 5 days before RNA or protein analysis.

Western blotting

Cells were harvested for protein analysis with standard lysis buffer containing 1% Triton X-100, 1 mM β -glycerophosphate, 2.5 mM Na₄P₂O₇, 20 mM NaF, 1 mM Na₃VO₄, 1 mM phenylmethylsulfonyl fluoride, and protease inhibitor mixture (Roche Applied Science). Proteins were boiled for 5 min in LDS loading buffer containing 0.1% β -mercaptoethanol and separated on a 4–12% BisTris SDS-PAGE (Life Technologies). Specific proteins were detected with antibodies directed against p-IRE1 α (Novus Bio), IRE1 α , actin (Santa Cruz Biotechnology), BiP/Grp78 (Stressgen), p-p38, p38, p-JNK, JNK, p-IEF2 α , eIF2 α , GFP, and CHOP (Cell Signaling Technologies), as shown in Table 1.

RNA and RT-PCR analysis

Total RNA was isolated from heart or cells with TRIzol (Life Technologies). For animal studies, cDNA was prepared using iScript Reverse Transcription Supermix and amplified with SsoFast EvaGreen Supermix on a CVX96 thermal cycler (all from Bio-Rad). For cell studies, cDNA was prepared using Superscript II (Invitrogen) and amplified with SYBR Green supermix on a MyIQ system (Bio-Rad). Melt curves were generated for each primer set during each experiment, and analysis was performed using the $\Delta\Delta C_T$ method (Table 2).

Xbp1 activation

IRE1 α RNase activity toward *Xbp1* mRNA was monitored by semiquantitative PCR. Both unspliced and spliced *Xbp1* mRNA were amplified with primers targeting the region surrounding the IRE1 α -dependent splicing site (forward, 5'-GTTCCA-GAGGTGGAGGCCA-3'; reverse, 5'-CATGACAGGGTCC-

Table 1
Antibodies

| Antibodies | Vendor | Catalog no. | Dilution |
|---------------------------|--------------------------|-------------|----------|
| p-IRE1 α (Ser-724) | Novus Bio | NB100-2323 | 1:1000 |
| IRE1 α | Santa Cruz Biotechnology | SC-20790 | 1:500 |
| Actin | Santa Cruz Biotechnology | SC-1616 | 1:1000 |
| CHOP | Santa Cruz Biotechnology | SC-7351 | 1:500 |
| BiP/Grp78 | Santa Cruz Biotechnology | SC-1050 | 1:500 |
| p-p38 | Cell Signaling | 9211 | 1:1000 |
| p38 | Cell Signaling | 9212 | 1:1000 |
| p-JNK | Cell Signaling | 9251 | 1:1000 |
| JNK | Cell Signaling | 9252 | 1:1000 |
| p-eIF2 α | Cell Signaling | 9721 | 1:1000 |
| eIF2 α | Cell Signaling | 9722 | 1:1000 |
| GFP | Cell Signaling | 2956 | 1:1000 |

Table 2
Primers

| Target | Sequence | |
|----------------------|-------------------------|--------------------------|
| | Forward | Reverse |
| For mouse | | |
| Xbp1 Total | TGGACTCTGACACTGTTGCC | CTCTGGGGAAGGACATTTGA |
| sXbp1 | CAGTGGTCGCCACCGTCCATC | TGCCCGGCCAGCCTTTCTA |
| Xbp1 splicing | GTTCAGAGGTGGAGGCCA | CATGACAGGTTCCAACCTGTCC |
| CHOP | TATCTCATCCCCAGGAAACG | GGGCACTGACCACTCTGTTT |
| BiP | GAGGCTGTAGCCTATGGTGC | TTTGTAGGGTCTGTCCACC |
| Rps26 | GCCTCTTTACATGGGCTTTG | GCCATCCATAGCAAGGTTGT |
| For mouse/rat | | |
| IRE1 α | ACGGTGGACATCTTTTCGC | TGGGGATCCATAGCAATCAT |
| IRE1 α MYC | TCAGGAGACGCTGGGCTCCATC | AGAGATCAGCTTCTGCTCGCCTC |
| ANF | CTGATGGATTTCAAGAACCTGCT | CTCTGGGCTCCAATCCTGTGC |
| β MHC | CTCAACTGGGAAGAGCATCCA | CCTTCAGCAACTCTGGAGGC |
| TNF α | CTCTTCAAGGGACAAGGCTG | TGGAAGACTCCTCCAGGTA |
| GAPDH | TCCTGCACCACCACTGCTTAG | GATGACCTTGCCACAGCCTTG |
| For rat | | |
| RatXBP1 | CTCAGAGGCAGAGTCCAAGG | ACAGGGTCCAACCTGTCCAG |
| sXBP1 | TCTGCTGAGTCCGCAGCAGG | CTTAAGACTAGAGCCTTGG |
| uXBP1 | CAGACTACGTGCGCCTCTGC | CTTCTGGGTAGACCTCTGGG |
| CHOP | CCTTCACTACTCTTGACCTGC | CGCTCGTTCTCTCAGCAAG |
| BIP | TTCCGCTTACCATGAAACC | CTTATTGTTACGGTGGCT |
| RPS26 | CGCTCTTCACGCTTACGTCG | ACCTCTTTACATGGGCTTTGGTGA |

IRE1 α function in heart

AACTTGTC-3'). Products were amplified with the cycling protocol of 95 °C for 30 s, followed by 35 cycles of 95 °C for 30 s, 60 °C for 30 s, and 72 °C for 25 s, followed by 72 °C for 10 min. PCR products were separated on 4% agarose gel.

Statistical analysis

Data are presented as mean \pm S.D. Means of two groups were compared by two-tailed Student's *t* test. Means of more than two groups were compared by analysis of variance and Turkey post hoc test. Differences between groups were considered statistically significant when $p < 0.05$.

Author contributions—D. S., T. Y., J. L., and S. R. data curation; D. S. formal analysis; D. S., T. Y., S. R., and Y. W. investigation; D. S. writing-original draft; T. Y. validation; T. Y. and Y. W. methodology; T. Y., S. M., and Y. W. writing-review and editing; S. R., S. M., and Y. W. supervision; S. M. and Y. W. conceptualization; S. M. funding acquisition; Y. W. resources; Y. W. project administration.

Acknowledgment—We thank Haiying Pu for technical assistance.

References

- Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., Fullerton, H. J., Gillespie, C., Hailpern, S. M., Heit, J. A., Howard, V. J., *et al.* (2012) Heart disease and stroke statistics—2012 update: a report from the American Heart Association. *Circulation* **125**, e2–e220 [CrossRef Medline](#)
- Lindholm, D., Wootz, H., and Korhonen, L. (2006) ER stress and neurodegenerative diseases. *Cell Death Differ.* **13**, 385–392 [CrossRef Medline](#)
- Marciniak, S. J., and Ron, D. (2006) Endoplasmic reticulum stress signaling in disease. *Physiol. Rev.* **86**, 1133–1149 [CrossRef Medline](#)
- Mitchell, S., Ota, A., Foster, W., Zhang, B., Fang, Z., Patel, S., Nelson, S. F., Horvath, S., and Wang, Y. (2006) Distinct gene expression profiles in adult mouse heart following targeted MAP kinase activation. *Physiol. Genomics* **25**, 50–59 [CrossRef Medline](#)
- Ron, D., and Hubbard, S. R. (2008) How IRE1 reacts to ER stress. *Cell* **132**, 24–26 [CrossRef Medline](#)
- Okada, K., Minamino, T., Tsukamoto, Y., Liao, Y., Tsukamoto, O., Takashima, S., Hirata, A., Fujita, M., Nagamachi, Y., Nakatani, T., Yutani, C., Ozawa, K., Ogawa, S., Tomoike, H., Hori, M., and Kitakaze, M. (2004) Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis. *Circulation* **110**, 705–712 [CrossRef Medline](#)
- Ellgaard, L., and Helenius, A. (2003) Quality control in the endoplasmic reticulum. *Nat. Rev. Mol. Cell Biol.* **4**, 181–191 [CrossRef Medline](#)
- Janero, D. R., Hreniuk, D., and Sharif, H. M. (1991) Hydrogen peroxide-induced oxidative stress to the mammalian heart-muscle cell (cardiomyocyte): lethal peroxidative membrane injury. *J. Cell. Physiol.* **149**, 347–364 [CrossRef Medline](#)
- Schröder, M., and Kaufman, R. J. (2005) ER stress and the unfolded protein response. *Mutat. Res.* **569**, 29–63 [CrossRef Medline](#)
- Bulleid, N. J. (2012) Disulfide bond formation in the mammalian endoplasmic reticulum. *Cold Spring Harb. Perspect. Biol.* **4**, a013219 [CrossRef Medline](#)
- Mori, K., Kawahara, T., Yoshida, H., Yanagi, H., and Yura, T. (1996) Signaling from endoplasmic reticulum to nucleus: transcription factor with a basic-leucine zipper motif is required for the unfolded protein-response pathway. *Genes Cells* **1**, 803–817 [CrossRef Medline](#)
- Tirasophon, W., Welihinda, A. A., and Kaufman, R. J. (1998) A stress response pathway from the endoplasmic reticulum to the nucleus requires a novel bifunctional protein kinase/endoribonuclease (Ire1p) in mammalian cells. *Genes Dev.* **12**, 1812–1824 [CrossRef Medline](#)
- Shen, X., Zhang, K., and Kaufman, R. J. (2004) The unfolded protein response—a stress signaling pathway of the endoplasmic reticulum. *J. Chem. Neuroanat.* **28**, 79–92 [CrossRef Medline](#)
- Urano, F., Wang, X., Bertolotti, A., Zhang, Y., Chung, P., Harding, H. P., and Ron, D. (2000) Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. *Science* **287**, 664–666 [CrossRef Medline](#)
- Lee, A. S. (2005) The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. *Methods* **35**, 373–381 [CrossRef Medline](#)
- Haze, K., Yoshida, H., Yanagi, H., Yura, T., and Mori, K. (1999) Mammalian transcription factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in response to endoplasmic reticulum stress. *Mol. Biol. Cell* **10**, 3787–3799 [CrossRef Medline](#)
- Harding, H. P., Zhang, Y., and Ron, D. (1999) Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. *Nature* **397**, 271–274 [CrossRef Medline](#)
- Shamu, C. E., and Walter, P. (1996) Oligomerization and phosphorylation of the Ire1p kinase during intracellular signaling from the endoplasmic reticulum to the nucleus. *EMBO J.* **15**, 3028–3039 [Medline](#)
- Glembotski, C. C. (2007) Endoplasmic reticulum stress in the heart. *Circ. Res.* **101**, 975–984 [CrossRef Medline](#)
- Prins, D., and Michalak, M. (2009) Endoplasmic reticulum proteins in cardiac development and dysfunction. *Can. J. Physiol. Pharmacol.* **87**, 419–425 [CrossRef Medline](#)
- Azfer, A., Niu, J., Rogers, L. M., Adamski, F. M., and Kolattukudy, P. E. (2006) Activation of endoplasmic reticulum stress response during the development of ischemic heart disease. *Am. J. Physiol. Heart Circ. Physiol.* **291**, H1411–H1420 [CrossRef Medline](#)
- Terai, K., Hiramoto, Y., Masaki, M., Sugiyama, S., Kuroda, T., Hori, M., Kawase, I., and Hirota, H. (2005) AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress. *Mol. Cell. Biol.* **25**, 9554–9575 [CrossRef Medline](#)
- Stadtman, E. R. (2004) Role of oxidant species in aging. *Curr. Med. Chem.* **11**, 1105–1112 [CrossRef Medline](#)
- Martindale, J. J., Fernandez, R., Thuerauf, D., Whittaker, R., Gude, N., Sussman, M. A., and Glembotski, C. C. (2006) Endoplasmic reticulum stress gene induction and protection from ischemia/reperfusion injury in the hearts of transgenic mice with a tamoxifen-regulated form of ATF6. *Circ. Res.* **98**, 1186–1193 [CrossRef Medline](#)
- Wang, Z. V., Deng, Y., Gao, N., Pedrozo, Z., Li, D. L., Morales, C. R., Criollo, A., Luo, X., Tan, W., Jiang, N., Lehrman, M. A., Rothermel, B. A., Lee, A. H., Lavandero, S., Mammen, P. P. A., *et al.* (2014) Spliced X-box binding protein 1 couples the unfolded protein response to hexosamine biosynthetic pathway. *Cell* **156**, 1179–1192 [CrossRef Medline](#)
- Kerkelä, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., Walters, B., Shevtsov, S., Pesant, S., Clubb, F. J., Rosenzweig, A., Salomon, R. N., Van Etten, R. A., Alroy, J., Durand, J. B., and Force, T. (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. *Nat. Med.* **12**, 908–916 [CrossRef Medline](#)
- Cook, A. R., Bardswell, S. C., Pretheshan, S., Dighe, K., Kanaganayagam, G. S., Jabr, R. I., Merkle, S., Marber, M. S., Engelhardt, S., and Avkiran, M. (2009) Paradoxical resistance to myocardial ischemia and age-related cardiomyopathy in NHE1 transgenic mice: a role for ER stress? *J. Mol. Cell Cardiol.* **46**, 225–233 [CrossRef Medline](#)
- Lynch, J. M., Maillet, M., Vanhoutte, D., Schloemer, A., Sargent, M. A., Blair, N. S., Lynch, K. A., Okada, T., Aronow, B. J., Osinska, H., Prywes, R., Lorenz, J. N., Mori, K., Lawler, J., Robbins, J., and Molkentin, J. D. (2012) A thrombospondin-dependent pathway for a protective ER stress response. *Cell* **149**, 1257–1268 [CrossRef Medline](#)
- Briot, A., Jaroszewicz, A., Warren, C. M., Lu, J., Touma, M., Rudat, C., Hofmann, J. J., Airik, R., Weinmaster, G., Lyons, K., Wang, Y., Kispert, A., Pellegrini, M., and Iruela-Arispe, M. L. (2014) Repression of Sox9 by Jag1 is continuously required to suppress the default chondrogenic fate of vascular smooth muscle cells. *Dev. Cell* **31**, 707–721 [CrossRef Medline](#)
- Thuerauf, D. J., Marcinko, M., Gude, N., Rubio, M., Sussman, M. A., and Glembotski, C. C. (2006) Activation of the unfolded protein response in

- infarcted mouse heart and hypoxic cultured cardiac myocytes. *Circ. Res.* **99**, 275–282 [CrossRef Medline](#)
31. Fu, H. Y., Minamino, T., Tsukamoto, O., Sawada, T., Asai, M., Kato, H., Asano, Y., Fujita, M., Takashima, S., Hori, M., and Kitakaze, M. (2008) Overexpression of endoplasmic reticulum-resident chaperone attenuates cardiomyocyte death induced by proteasome inhibition. *Cardiovasc. Res.* **79**, 600–610 [CrossRef Medline](#)
 32. Groenendyk, J., and Michalak, M. (2005) Endoplasmic reticulum quality control and apoptosis. *Acta Biochim. Pol.* **52**, 381–395 [Medline](#)
 33. Kadowaki, H., Nishitoh, H., and Ichijo, H. (2004) Survival and apoptosis signals in ER stress: the role of protein kinases. *J. Chem. Neuroanat.* **28**, 93–100 [CrossRef Medline](#)
 34. Kim, R., Emi, M., Tanabe, K., and Murakami, S. (2006) Role of the unfolded protein response in cell death. *Apoptosis* **11**, 5–13 [CrossRef Medline](#)
 35. Zhang, C., Kawachi, J., Adachi, M. T., Hashimoto, Y., Oshiro, S., Aso, T., and Kitajima, S. (2001) Activation of JNK and transcriptional repressor ATF3/LRF1 through the IRE1/TRAF2 pathway is implicated in human vascular endothelial cell death by homocysteine. *Biochem. Biophys. Res. Commun.* **289**, 718–724 [CrossRef Medline](#)
 36. Hetz, C., Bernasconi, P., Fisher, J., Lee, A. H., Bassik, M. C., Antonsson, B., Brandt, G. S., Iwakoshi, N. N., Schinzel, A., Glimcher, L. H., and Korsmeyer, S. J. (2006) Proapoptotic BAX and BAK modulate the unfolded protein response by a direct interaction with IRE1 α . *Science* **312**, 572–576 [CrossRef Medline](#)
 37. Ogata, M., Hino, S., Saito, A., Morikawa, K., Kondo, S., Kanemoto, S., Murakami, T., Taniguchi, M., Tani, I., Yoshinaga, K., Shiosaka, S., Hammarback, J. A., Urano, F., and Imaizumi, K. (2006) Autophagy is activated for cell survival after endoplasmic reticulum stress. *Mol. Cell. Biol.* **26**, 9220–9231 [CrossRef Medline](#)
 38. Blais, J. D., Filipenko, V., Bi, M., Harding, H. P., Ron, D., Koumenis, C., Wouters, B. G., and Bell, J. C. (2004) Activating transcription factor 4 is translationally regulated by hypoxic stress. *Mol. Cell. Biol.* **24**, 7469–7482 [CrossRef Medline](#)
 39. Zhang, K., and Kaufman, R. J. (2004) Signaling the unfolded protein response from the endoplasmic reticulum. *J. Biol. Chem.* **279**, 25935–25938 [CrossRef Medline](#)
 40. Oyadomari, S., and Mori, M. (2004) Roles of CHOP/GADD153 in endoplasmic reticulum stress. *Cell Death Differ.* **11**, 381–389 [CrossRef Medline](#)
 41. Zinszner, H., Kuroda, M., Wang, X., Batchvarova, N., Lightfoot, R. T., Remotti, H., Stevens, J. L., and Ron, D. (1998) CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. *Genes Dev.* **12**, 982–995 [CrossRef Medline](#)
 42. Ghosh, R., Wang, L., Wang, E. S., Perera, B. G., Igarria, A., Morita, S., Prado, K., Thamsen, M., Caswell, D., Macias, H., Weiberth, K. F., Gliedt, M. J., Alavi, M. V., Hari, S. B., Mitra, A. K., et al. (2014) Allosteric inhibition of the IRE1 α RNase preserves cell viability and function during endoplasmic reticulum stress. *Cell* **158**, 534–548 [CrossRef Medline](#)
 43. Han, D., Lerner, A. G., Vande Walle, L., Upton, J. P., Xu, W., Hagen, A., Backes, B. J., Oakes, S. A., and Papa, F. R. (2009) IRE1 α kinase activation modes control alternate endonuclease outputs to determine divergent cell fates. *Cell* **138**, 562–575 [CrossRef Medline](#)
 44. Ishikawa, T. O., and Herschman, H. R. (2006) Conditional knockout mouse for tissue-specific disruption of the cyclooxygenase-2 (Cox-2) gene. *Genesis* **44**, 143–149 [CrossRef Medline](#)
 45. Sohal, D. S., Nghiem, M., Crackower, M. A., Witt, S. A., Kimball, T. R., Tymitz, K. M., Penninger, J. M., and Molkentin, J. D. (2001) Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. *Circ. Res.* **89**, 20–25 [CrossRef Medline](#)
 46. Hayashi, S., and McMahon, A. P. (2002) Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. *Dev. Biol.* **244**, 305–318 [CrossRef Medline](#)
 47. Petrich, B. G., Molkentin, J. D., and Wang, Y. (2003) Temporal activation of c-Jun N-terminal kinase in adult transgenic heart via cre-loxP-mediated DNA recombination. *FASEB J.* **17**, 749–751 [CrossRef Medline](#)
 48. Rockman, H. A., Ross, R. S., Harris, A. N., Knowlton, K. U., Steinhilber, M. E., Field, L. J., Ross, J., Jr., and Chien, K. R. (1991) Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an *in vivo* murine model of cardiac hypertrophy. *Proc. Natl. Acad. Sci. U.S.A.* **88**, 8277–8281 [CrossRef Medline](#)
 49. Wang, Y., Huang, S., Sah, V. P., Ross, J., Jr., Brown, J. H., Han, J., and Chien, K. R. (1998) Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. *J. Biol. Chem.* **273**, 2161–2168 [CrossRef Medline](#)
 50. Hu, P., Han, Z., Couvillon, A. D., Kaufman, R. J., and Exton, J. H. (2006) Autocrine tumor necrosis factor α links endoplasmic reticulum stress to the membrane death receptor pathway through IRE1 α -mediated NF- κ B activation and down-regulation of TRAF2 expression. *Mol. Cell. Biol.* **26**, 3071–3084 [CrossRef Medline](#)
 51. Isodono, K., Takahashi, T., Imoto, H., Nakanishi, N., Ogata, T., Asada, S., Adachi, A., Ueyama, T., Oh, H., and Matsubara, H. (2010) PARM-1 is an endoplasmic reticulum molecule involved in endoplasmic reticulum stress-induced apoptosis in rat cardiac myocytes. *PLoS One* **5**, e9746 [CrossRef Medline](#)
 52. Miyazaki, Y., Kaikita, K., Endo, M., Horio, E., Miura, M., Tsujita, K., Hokimoto, S., Yamamuro, M., Iwakawa, T., Gotoh, T., Ogawa, H., and Oike, Y. (2011) C/EBP homologous protein deficiency attenuates myocardial reperfusion injury by inhibiting myocardial apoptosis and inflammation. *Arterioscler. Thromb. Vasc. Biol.* **31**, 1124–1132 [CrossRef Medline](#)
 53. Zeng, L., Zampetaki, A., Margariti, A., Pepe, A. E., Alam, S., Martin, D., Xiao, Q., Wang, W., Jin, Z. G., Cockerill, G., Mori, K., Li, Y. S., Hu, Y., Chien, S., and Xu, Q. (2009) Sustained activation of XBP1 splicing leads to endothelial apoptosis and atherosclerosis development in response to disturbed flow. *Proc. Natl. Acad. Sci. U.S.A.* **106**, 8326–8331 [CrossRef Medline](#)
 54. Wang, X. Z., Harding, H. P., Zhang, Y., Jolicoeur, E. M., Kuroda, M., and Ron, D. (1998) Cloning of mammalian Ire1 reveals diversity in the ER stress responses. *EMBO J.* **17**, 5708–5717 [CrossRef Medline](#)
 55. Calton, M., Zeng, H., Urano, F., Till, J. H., Hubbard, S. R., Harding, H. P., Clark, S. G., and Ron, D. (2002) IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. *Nature* **415**, 92–96 [CrossRef Medline](#)
 56. Lisbona, F., Rojas-Rivera, D., Thielen, P., Zamorano, S., Todd, D., Martignon, F., Glavic, A., Kress, C., Lin, J. H., Walter, P., Reed, J. C., Glimcher, L. H., and Hetz, C. (2009) BAX inhibitor-1 is a negative regulator of the ER stress sensor IRE1 α . *Mol. Cell* **33**, 679–691 [CrossRef Medline](#)
 57. Ota, A., and Wang, Y. (2012) Cdc37/Hsp90 protein-mediated regulation of IRE1 α protein activity in endoplasmic reticulum stress response and insulin synthesis in INS-1 cells. *J. Biol. Chem.* **287**, 6266–6274 [CrossRef Medline](#)
 58. Lu, G., Ota, A., Ren, S., Franklin, S., Rau, C. D., Ping, P., Lane, T. F., Zhou, Z. H., Reue, K., Lusa, A. J., Vondriska, T., and Wang, Y. (2013) PPM1 ϵ encodes an inositol requiring-protein 1 (IRE1) specific phosphatase that regulates the functional outcome of the ER stress response. *Mol. Metab.* **2**, 405–416 [CrossRef Medline](#)
 59. Li, M., Georgakopoulos, D., Lu, G., Hester, L., Kass, D. A., Hasday, J., and Wang, Y. (2005) p38 MAP kinase mediates inflammatory cytokine induction in cardiomyocytes and extracellular matrix remodeling in heart. *Circulation* **111**, 2494–2502 [CrossRef Medline](#)
 60. Yokota, T., and Wang, Y. (2016) p38 MAP kinases in the heart. *Gene* **575**, 369–376 [CrossRef Medline](#)
 61. Liao, P., Georgakopoulos, D., Kovacs, A., Zheng, M., Lerner, D., Pu, H., Saffitz, J., Chien, K., Xiao, R. P., Kass, D. A., and Wang, Y. (2001) The *in vivo* role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. *Proc. Natl. Acad. Sci. U.S.A.* **98**, 12283–12288 [CrossRef Medline](#)
 62. Streicher, J. M., Ren, S., Herschman, H., and Wang, Y. (2010) MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart. *Circ. Res.* **106**, 1434–1443 [CrossRef Medline](#)
 63. Iwaki, K., Sukhatme, V. P., Shubeita, H. E., and Chien, K. R. (1990) α - and β -adrenergic stimulation induces distinct patterns of immediate early gene expression in neonatal rat myocardial cells: fos/jun expression is associated with sarcomere assembly; Egr-1 induction is primarily an α 1-mediated response. *J. Biol. Chem.* **265**, 13809–13817 [Medline](#)